KYORIN Pharmaceutical Co.,Ltd. AI Stock Analysis
Want to see JP:4569 full AI Analyst Report?
KYORIN Pharmaceutical Co.,Ltd. (4569) AI Stock Analysis
KYORIN Pharmaceutical Co.,Ltd.
(TSE/TYO:4569)
KYORIN Pharmaceutical scores poorly overall, driven primarily by weak financial performance. Despite a conservatively managed, low-leverage balance sheet, profitability is thin and deteriorating, with FY2026 projections pointing to revenue contraction, a sharp margin squeeze, and a roughly 62% fall in net income. Cash flow generation is unreliable, with three straight years of negative free cash flow. Technically, the stock remains in a longer-term downtrend well below its 200-day moving average with negative MACD, though it has begun to stabilize around its short-term averages. Valuation offers little support: a 165x P/E reflects depressed earnings, and while the 4.2% dividend yield is appealing, its durability is uncertain given weak cash generation. The low beta of 0.45 provides some defensive cushion, but it does not offset the fundamental deterioration.
KYORIN Pharmaceutical Co.,Ltd. (4569) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 57.64B
- Dividend Yield
- 4.32%
- Average Volume (3M)
- 205.24K
- Price to Earnings (P/E)
- 160.8
- Beta (1Y)
- 0.40
- Revenue Growth
- -6.48%
- EPS Growth
- -95.83%
- Country
- Japan
- Employees
- 1,982
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
KYORIN Pharmaceutical Co.,Ltd. Business Overview & Revenue Model
Company Description
Based in Tokyo, Japan, and founded in 1923, KYORIN Holdings, Inc. is a pharmaceutical enterprise engaged in the discovery, development, production, and worldwide distribution of both innovative prescription drugs and generic equivalents. Its diverse...
KYORIN Pharmaceutical Co.,Ltd. Financial Statement Overview
Summary
Financials are mixed-to-weak. The balance sheet is the clear strength (score 68), with low debt-to-equity of 0.16–0.21, steadily growing assets and equity, though ROE of just 3.2%–6.7% signals poor capital efficiency. The income statement (score 42) shows solid multi-year revenue growth to ¥130.1B in FY2025, but gross margins have eroded from ~50% to ~46%, and FY2026 guidance implies a ~4.3% revenue decline, a collapse in EBIT margin to ~2.8%, and a ~62% drop in net income. Cash flow is the weakest link (score 35), with volatile operating cash flow and three consecutive years of negative free cash flow through FY2025, raising earnings-quality and self-funding concerns.
Income Statement
42NeutralBalance Sheet
68PositiveCash Flow
35Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 125.02B | 126.26B | 130.09B | 119.53B | 113.27B | 105.53B |
| Gross Profit | 49.10B | 51.61B | 59.51B | 51.62B | 50.16B | 49.44B |
| EBITDA | 7.19B | 8.22B | 17.15B | 10.52B | 8.96B | 8.72B |
| Net Income | 388.00M | 3.45B | 9.09B | 5.47B | 4.72B | 3.93B |
Balance Sheet | ||||||
| Total Assets | 186.82B | 195.46B | 193.62B | 177.63B | 176.04B | 171.92B |
| Cash, Cash Equivalents and Short-Term Investments | 23.24B | 15.08B | 16.51B | 13.98B | 19.39B | 27.49B |
| Total Debt | 23.17B | 23.79B | 28.44B | 20.95B | 21.28B | 21.62B |
| Total Liabilities | 48.76B | 53.02B | 57.33B | 46.89B | 50.58B | 47.41B |
| Stockholders Equity | 138.06B | 142.43B | 136.28B | 130.74B | 125.46B | 124.51B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 2.52B | -2.19B | -4.23B | -4.32B | 3.90B |
| Operating Cash Flow | 0 | 6.38B | 3.51B | 1.55B | 2.01B | 6.35B |
| Investing Cash Flow | 0 | -1.64B | -6.32B | -3.19B | -6.28B | -2.56B |
| Financing Cash Flow | 0 | -7.96B | 3.95B | -3.35B | -3.36B | -4.11B |
KYORIN Pharmaceutical Co.,Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4569, the sentiment is Negative. The current price of 1087.00 is below the 20-day moving average (MA) of 1099.60, below the 50-day MA of 1097.95, and below the 200-day MA of 1304.63, indicating a bearish trend. The MACD of -1.80 indicates Negative momentum. The RSI at 47.31 is Neutral, neither overbought nor oversold. The STOCH value of 61.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4569.
KYORIN Pharmaceutical Co.,Ltd. Peers Comparison
Overall Rating
JP:451674Outperform
JP:453473Outperform
JP:454773Outperform
JP:452153Neutral
JP:455350Neutral
JP:456946Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 74Outperform | JPY 222.40B | 7.56 | ― | 3.76% | 17.69% | -7.87% | |
| 73Outperform | JPY 114.51B | 11.06 | 7.68% | 2.45% | 15.85% | 60.55% | |
| 73Outperform | JPY 178.50B | 16.21 | 4.95% | 4.69% | 5.87% | -21.16% | |
| 53Neutral | JPY 137.05B | 15.74 | 6.11% | 4.99% | 5.43% | 1167.62% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | JPY 160.44B | 41.13 | 2.10% | 2.45% | 7.06% | -81.10% | |
| 46Neutral | JPY 57.22B | 160.80 | ― | 4.32% | -6.48% | -95.83% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4569 | KYORIN Pharmaceutical Co.,Ltd. | 1087.00 | -348.63 | -24.28% | |
| JP:4521 | Kaken Pharmaceutical Co | 3805.00 | 189.53 | 5.24% | |
| JP:4547 | Kissei Pharmaceutical Co | 4370.00 | 35.73 | 0.82% | |
| JP:4553 | Towa Pharmaceutical Co | 3260.00 | 188.49 | 6.14% | |
| JP:4534 | Mochida Pharmaceutical Co., Ltd. | 3365.00 | 84.75 | 2.58% | |
| JP:4516 | Nippon Shinyaku Co., Ltd. | 3302.00 | -219.85 | -6.24% |
KYORIN Pharmaceutical Co.,Ltd. Corporate Events
KYORIN, Acadia Enter Japan Distribution Agreement for DAYBUE STIX
KYORIN Pharmaceutical operates in the pharmaceutical industry, with stated activities including developing high-value new drugs and expanding its development pipeline through in-licensing for the Japanese market. It entered an exclusive distribution...
KYORIN Announces Second-Quarter Consolidated Results Release
KYORIN Pharmaceutical announced its second-quarter consolidated financial results for the fiscal year ending March 31, 2027. The supplied text lists sections covering business performance, financial results, product sales, research and development ex...
KYORIN Gains Japanese Rights to Edesa’s EB05 ARDS Therapy
KYORIN Pharmaceutical is a Japanese pharmaceutical company that develops and commercializes prescription medicines, particularly treatments addressing unmet medical needs. It has secured exclusive rights in Japan to develop and commercialize Edesa Bi...
KYORIN Reports Mixed Interim Results, Cuts Full-Year Earnings Outlook
KYORIN Pharmaceutical reported interim net sales of ¥57.489 billion, slightly below its forecast, as sales of Lasvic and Mucodyne underperformed expectations. Operating profit and ordinary profit exceeded forecasts because selling, general and admini...
Kyorin Reports First-Half Net Loss as Profits Decline
KYORIN Pharmaceutical is a pharmaceutical company; the release does not detail its primary products or specific market focus.For the six months ended September 30, 2026, consolidated sales fell 2.1% year on year to ¥57.489 billion, while operating pr...
Kopernik Global Investors Lifts Stake in KYORIN Pharmaceutical to Over 10%
KYORIN Pharmaceutical Co., Ltd., a TSE Prime-listed Japanese pharmaceutical manufacturer, develops and markets prescription pharmaceuticals and healthcare-related products. Its shares are held by a mix of domestic and overseas institutional investors...
Kyorin to Divest Generic Drug Unit to New PCPI Platform, Sharpen Focus on New Drugs
KYORIN Pharmaceutical has signed a definitive agreement to transfer its generic drug business, including subsidiary KYORIN Rimedio and two manufacturing plants, to Pharmatech Co‑creation Platform Inc., a new entity to be jointly established by Daito...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 17, 2026